Professor Richard Scolyer dies aged 59 leaving behind legacy of revolutionary brain cancer research

Professor Richard Scolyer, a renowned Australian melanoma pathologist and former Australian of the Year, died at 59 after a three-year fight against glioblastoma, an aggressive brain cancer with an average survival rate of 12 months. Scolyer became a global pioneer when he volunteered as 'patient zero' for an experimental immunotherapy treatment, developed by himself and colleagues at the Melanoma Institute of Australia, including co-director Georgina Long. Scolyer’s case proved groundbreaking: he underwent immunotherapy before tumor removal, a radical approach based on melanoma research. Despite a terminal prognosis, he lived more than two and a half years, far exceeding expectations. His condition briefly worsened in March 2025, but he remained optimistic, expressing gratitude for public support in interviews with ABC Radio Sydney and Australian Story. In an open letter published posthumously, Scolyer reflected on his life’s work, emphasizing transparency about cancer treatment challenges and the importance of pushing scientific boundaries. He encouraged others to embrace opportunities and contribute meaningfully, even in difficult circumstances. His social media updates during treatment kept supporters worldwide informed about his journey. Diagnosed in 2023 at age 56 with IDH 'wild' type glioblastoma, Scolyer described his fight as a mission to defy medical limitations. He called his decision to pursue the unproven treatment a 'no-brainer,' prioritizing contribution and quality of life over resignation. His legacy includes advancing immunotherapy research and inspiring patients and families facing terminal illnesses to advocate for progress in cancer care.